On October 17, the PTAB denied institution of IPR2016-000912, IPR2016-00915, IPR2016-00916. The Petitions in these cases were filed by Swiss Pharma International AG on U.S. Patent Nos. 8,815,236; 8,349,321; and 8,900,577, respectively, all owned by Biogen. The patents all relate to compositions of natalizumab, marketed by Biogen under the brand-name…
IPR2016-00912 (Swiss Pharma Int’l AG) (U.S. Pat. No. 8,815,236) Petitioner: Swiss Pharma Int’l AG Patent: U.S. Patent No. 8,815,236 Patent Title: Method of Treating Multiple Sclerosis and Crohn’s Disease Patent Assignee: Biogen Idec MA, Inc. IPR2016-00915 (Swiss Pharma Int’l AG) (U.S. Pat. No. 8,349,321) Petitioner: Swiss Pharma Int’l AG Patent:…